Exosomes from adipose‐derived stem cells and application to skin wound healing

Yang An,Shuyan Lin,Xiaojie Tan,Shiou Zhu,Fangfei Nie,Yonghuan Zhen,Luosha Gu,Chunlei Zhang,Baicheng Wang,Wei Wei,Dong Li,Junhao Wu

DOI: https://doi.org/10.1111/cpr.12993

IF: 8.755

2021-01-17

Cell Proliferation

Abstract:<p>Skin wound healing is an intractable problem that represents an urgent clinical need. To solve this problem, a large number of studies have focused on the use of exosomes (EXOs) derived from adipose‐derived stem cells (ADSCs). This review describes the mechanisms whereby ADSCs‐EXOs regulate wound healing and their clinical application. In the wound, ADSCs‐EXOs modulate immune responses and inflammation. They also promote angiogenesis, accelerate proliferation and re‐epithelization of skin cells, and regulate collagen remodelling which inhibits scar hyperplasia. Compared with ADSCs therapeutics, ADSCs‐EXOs have highly stability and are easily stored. Additionally, they are not rejected by the immune system and have a homing effect and their dosage can be easily controlled. ADSCs‐EXOs can improve fat grafting and promote wound healing in patients with diabetes mellitus. They can also act as a carrier and combined scaffold for treatment, leading to scarless cutaneous repair. Overall, ADSCs‐EXOs have the potential to be used in the clinic to promote wound healing.</p>

cell biology

What problem does this paper attempt to address?

The paper primarily explores the application and mechanisms of adipose-derived stem cell exosomes (ADSCs-EXOs) in skin wound healing. Specifically, the paper focuses on the following aspects:

1. **Regulation of Immune Response and Inflammation**: ADSCs-EXOs can inhibit T cell activation by reducing the secretion of interferon-α (IFN-α), thereby alleviating inflammatory responses. Additionally, they can induce macrophage differentiation into the M1 type by carrying specific miRNAs (such as miR-155), influencing the inflammation process.

2. **Promotion of Angiogenesis at the Wound Site**: ADSCs-EXOs are rich in components such as miRNA-125a and miRNA-31, which can be delivered to vascular endothelial cells, thereby stimulating their proliferation and migration, enhancing angiogenesis.

3. **Acceleration of Skin Cell Proliferation and Re-epithelialization**: After being absorbed by skin fibroblasts, ADSCs-EXOs can promote cell proliferation, migration, and collagen synthesis in a dose-dependent manner, thereby accelerating the skin regeneration process.

4. **Regulation of Collagen Remodeling to Inhibit Excessive Scar Formation**: In the early stages of healing, ADSCs-EXOs promote the synthesis of type I and type III collagen; in the later stages, they reduce scar formation by inhibiting collagen formation.

5. **Clinical Applications**:
- **Improvement of Fat Grafting Outcomes**: ADSCs-EXOs can enhance the success rate of fat grafting by promoting angiogenesis and regulating inflammatory responses.
- **Promotion of Wound Healing in Diabetic Patients**: ADSCs-EXOs can effectively promote wound healing in diabetic mice, providing an experimental basis for treating chronic diabetic ulcers.
- **As Drug Carriers and Combined Scaffold Materials**: Utilizing the biocompatibility and targeting properties of EXOs, they can be used as drug carriers and combined with scaffold materials such as hydrogels or fibrin to stabilize their concentration, further enhancing wound healing capabilities.
- **Promotion of Scarless Skin Repair**: Studies suggest that ADSCs-EXOs may become a new treatment method for scarless skin repair.

In summary, ADSCs-EXOs show great potential in promoting skin wound healing. They can regulate immune responses and inflammation, promote angiogenesis, accelerate skin cell proliferation and re-epithelialization, and regulate collagen remodeling to reduce scar formation. These characteristics make ADSCs-EXOs promising for clinical applications. However, despite their proven efficacy, their specific mechanisms of action require further research. Additionally, simple methods for extracting and purifying ADSCs-EXOs and standardized identification methods need to be addressed.